BACKGROUND: Low-grade gliomas (LGGs) comprise a diverse set of intrinsic brain tumors that correlate strongly with survival. Data on the effect of reoperation are sparse. OBJECTIVE: To evaluate the effect of reoperation on patients with LGG. METHODS: Fifty-two consecutive patients with reoperated LGGs treated at the University of Washington between 1986 and 2004 were identified and evaluated in a retrospective analysis. RESULTS: The average overall survival (OS) for this cohort was 12.95 6 0.96 years. The overall 10-year survival rate was 57%. The absence of any residual tumor at either the first or second operation was associated with significantly increased OS. Negative prognostic variables for OS included the use of upfront radiation and pathology at recurrence. The average overall progression-free survival to the first recurrence (PFS1) was 6.23 6 0.51 years. Positive prognostic factors for improved PFS1 included the use of upfront radiation therapy. Variables not associated with differences in PFS1 included the use of upfront chemotherapy, enhancement, pathology, extent of resection, the presence of residual tumor, and Karnofsky Performance Scale score ,80. The average overall progression-free survival to the second recurrence was 2.73 6 0.39 years. Pathology at recurrence was associated with significant differences in progression-free survival to the second recurrence, as was extent of resection at time of first recurrence, and Karnofsky Performance Scale score ,80. CONCLUSION: This is among the largest studies to assess variables associated with outcome in patients with reoperated LGG. Reresection appears to provide significant benefit, and extent of resection remains the strongest predictor of OS.
L ow-grade gliomas (World Health Organization [WHO] grade II astrocytomas, oligodendrogliomas, and oligoastrocytomas) are a diverse set of primary brain tumors that are characteristically diffuse and slow growing. These tumors tend to recur, often with malignant degeneration after primary treatment. 1 Prognosis and optimal management depend on myriad factors, including age, Karnofsky Performance Scale (KPS) score, symptomatology, tumor diameter, bilaterality, histology, and molecular genetic markers. [2] [3] [4] [5] Strong evidence over the last 2 decades has implicated extent of resection (EOR) as a major factor influencing patient overall survival (OS). [1] [2] [3] [4] 6, 7 Low-grade gliomas carry a better prognosis than glioblastoma or anaplastic astrocytoma (approximate median survivals, 13 and 41 months, respectively), but the vast majority of patients still die of disease progression. Despite strategies incorporating adjuvant chemotherapy and radiation at the time of diagnosis, 5-year survival ranges from 42% to 92%. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Despite these data, the role of reresection in the management of recurrent low-grade gliomas has not been clearly studied. 26 In this study, we sought to elucidate the role of reresection in a retrospective cohort of patients treated at a single institution.
METHODS
In this retrospective, cohort study, consecutive adult patients (age . 18 years) who underwent initial surgery and reresection at the University of Washington for a low-grade glioma (astrocytoma, oligodendroglioma, and oligoastrocytoma) between 1986 and 2004 were identified and classified with the use of the Bauman et al 3 recursive partitioning analysis (RPA). Patients with gemicystocytic histology or gliomatosis cerebri at diagnosis were excluded, as were patients who underwent biopsy only. Pathology was determined according to WHO guidelines. 27 Electronic medical records and, when needed, paper charts were used. For included patients, there was complete follow-up ( Figure 1 ). This study was approved by the University of Washington Institutional Review Board, protocol 31528.
Outcome measurements included OS, time to first progression (PFS1), and time to second progression (PFS2). OS was defined as the time between initial surgery and death. PFS1 was defined as the time between initial surgery and demonstration of an unequivocal increase in tumor size on follow-up imaging or malignant progression. PFS2 was defined as the time between intervention at the first recurrence and subsequent recurrence on imaging. Patients with no known progression were censored as of their last scan date. This strategy of defining progression as the time of observable change in imaging has been validated previously. 4 
Surgery
All patients underwent anatomic resections using subpial technique 28 and functional mapping for tumors involving eloquent cortex. Nearly 90% of patients underwent surgery with neuronavigation. Resectability was determined by the ability to remove the vast majority of tumor without causing functional deficits. The goal of operations was maximum resection of all or fluid-attenuated inversion recovery (FLAIR)-observable disease or T2 disease (in those few patients who preceded wide adoption of the FLAIR sequence) and removal of all contrast-enhancing disease. Tumors that crossed the corpus callosum were amputated such that homologous contralateral brain was not injured. Neuronavigation, intraoperative ultrasound, and functional mapping were used to execute this surgical strategy as needed. The decision to reoperate was based primarily on unequivocal evidence of tumor regrowth on magnetic resonance imaging (MRI).
Imaging Analysis
EOR was defined as a percentage (ie, .90%) or as the evidence of any residual observable on postoperative imaging (postoperative day 1). FLAIR axial slices were used during the first and second perioperative periods. In cases of tumor transformation, contrast-enhancing disease was measured. Follow-up imaging ranged from 3 to 6 months (or if new symptoms developed), depending on the individual practitioner choice.
Statistical Analysis
Frequency distributions and summary statistics were calculated for all variables. For categorical variables, cross-tabulations were generated, and Wilcoxon tests and Fisher tests were used to compare their distributions. The Kaplan-Meier method was used to estimate cumulative survival for OS, PFS1, and PFS2.
Univariate OS, PFS1, and PFS2 analyses using proportional hazards models were used to assess the prognostic significance of multiple variables. Cox regression was used for multivariate analyses. All P values were from 2-sided tests, with statistical significance defined as P , .05. Analyses were performed with standard statistical software (SPSS, IBM Inc).
RESULTS

Participants and Descriptive Data
In total, 52 patients met inclusion criteria, and their characteristics are shown in Table 1 (data are expressed as mean 6 SE). The mean follow-up was 15.9 years (range, 2.1-27.3 years). At diagnosis, the majority of patients were Bauman et al 3 RPA class 4 with a preponderance of male patients (62%, n = 32) and an average KPS score of 97.12 6 1.2. The vast majority (71%, n = 37) had a .90% removal of their FLAIR abnormality in a study population in which 30% (n = 16) had subtotal resections as a result of invasion of functional cortex. Eight percent (n = 4) of patients underwent an awake language mapping procedure to maximize resection while preserving function. 4, 19, 29, 30 At the time of first recurrence, there was a migration of patients to RPA classes 1 (n = 1) and 2 and 3 (36%), but the majority still remained class 4 (61%), with an average KPS score of 92.50 6 1.69 (median, 100). The vast majority (73%, n = 38) received a .90% resection, with 54% (n = 28) still showing some residual disease in postoperative follow-up. This is in a population in which 48% were not fully resectable from a functional perspective at the time of the second operation. Twenty-three percent of patients (n = 12) underwent awake language mapping, and 46% of patients (n = 24) underwent motor and somatosensory evoked potential mapping. As expected, the pathology at recurrence showed a substantial number of patients with malignant degeneration (Table 1) . For tumors that remained low grade at recurrence, 10 were oligoastrocytoma, 3 were astrocytoma, and 15 were oligodendroglioma, in keeping with previously reported data on more favorable transformation rates with oligodendroglioma. 31 Fifteen patients progressed to anaplastic status, and 9 progressed to grade IV status at recurrence. A far higher percentage of patients received chemotherapy (71%, n = 37) and radiation (56%, n = 29) at the time of recurrence. Fractionated external beam radiation therapy, when delivered, was dosed between 5400 and 5900 cGy.
Main Results
Overall Survival
The average median survival for this cohort of patients was 12.95 6 0.96 years. The overall 10-year cumulative survival rate was 57% (95% confidence interval [CI], . Table 2 provides the overall results. In brief, pathology at diagnosis was not associated with significant differences in OS (Figure 2 ). The presence of any residual tumor at either the first (P =.007) or second (P =.001) operation was associated with significantly decreased OS (Figure 3 ). Variables such as the use of upfront radiation, pathology at recurrence, and percentage tumor resection at second surgery were also associated with significant differences in OS (Figure 4 ). In addition, those patients who did not receive upfront radiation (n = 19) had a 23.6% 6 10.3 chance of malignant degeneration at their second operation compared with those who did receive upfront radiation (n = 33, 70.0% 6 8.1; P ,.001). Moreover, there was a trend of improved OS in patients who underwent procarbazine, lomustine, and vincristine (PCV; n = 4) chemotherapy rather than temozolomide in those patients with recurrent low-grade tumors (hazard ratio, 0.23; 95% CI, 0.05-1.15; P = .07).
Variables not associated with differences in OS included sex, KPS score ,80, enhancement at either initial or repeat surgery, upfront chemotherapy, pathology at diagnosis, use of radiation at recurrence, chemotherapy at recurrence, or RPA class. Tumors that crossed the midline at diagnosis and at recurrence did not show a significant difference in OS (P = .11 and P = .09, respectively). (30) 25 (48) a EBRT, external beam radiation therapy; KPS, Karnofsky Performance Scale; RPA, recursive partitioning analysis.
OUTCOMES IN REOPERATED LOW-GRADE GLIOMAS
Progression-Free Survival to First Recurrence The PFS1 was 6.23 6 0.51 years. The 5-year progression-free survival rate was 60% (95% CI, . The use of upfront radiation was associated with a significant increase in PFS1 ( Figure 4B ).
Variables not associated with differences in PFS1 included the use of upfront chemotherapy, enhancement, pathology, extent of tumor resection, the presence of residual tumor, whether the tumor was fully resectable, and KPS score ,80.
Progression-Free Survival After Surgically Treated Recurrence
A total of 78.4% of patients progressed after treatment for their first surgical recurrence. The median overall PFS2 was 2.73 6 0.39 years. Higher-grade tumors were associated with significant differences in PFS2, as was extent of tumor resection at time of first recurrence ( Figure 5 ), presence of residual after operation for recurrence, resectability, and KPS score ,80.
Factors not associated with differences in PFS2 included RPA class, enhancement, tumor crossing the midline, or use of radiation. The use of chemotherapy for tumors that retained low-grade status at recurrence was associated with a disadvantage (Figure 6 ).
Multiple Regression Analysis
Given the limited sample size, multiple regression could only be performed for 2 variables simultaneously. In this analysis, the effect of having any residual disease after operation 1 or operation 2 on OS proved to still be significant even when considering age, pathology, use of radiotherapy, and use of chemotherapy.
Tumor Change Ahead of Enhancement
In 6 patients after initial surgery, surveillance imaging revealed subtle, resectable changes in the white matter that preceded enhancement at an average of 517 6 77 days (initial pathology Figure 7 ). Four patients had residual disease after initial surgery; upfront adjuvant radiation was used in 4 cases, and no patient received upfront chemotherapy. In all cases, pathology at recurrence indicated a higher-grade lesion. Comparison of OS with patients whose pathology remained low grade showed a nearly significant decrease in OS (14.8 6 1.2 vs 11.0 6 2.6; P = .07), suggesting a window for treatment opportunity.
Multiple Surgeries
Eight patients had 3 surgeries and 2 patients had 4 surgeries. When these 10 patients were compared with those undergoing only 2 surgeries, OS was not significantly different (hazard ratio, 1.14; 95% CI, 0.525-2.5; P = .74). Of these patients, 5 retained low-grade pathology at the third surgery, and 5 patients progressed to anaplastic glioma (WHO grade III) status.
DISCUSSION Key Results
This study demonstrates that the absence of residual disease after the initial operation (16.7 6 1.8 vs 10.5 6 1.0; P = .004) and at recurrence (17.2 6 1.7 vs 9.8 6 0.9; P , .001) is associated with improvement in OS ( Figure 3A and 3B) . Adjuvant radiation after initial operation does not appear to confer any OS benefit.
Interpretation
The role of repeat aggressive surgeries for WHO grade II infiltrative gliomas remains unclear. Although the role of resective surgery for the initial presentation of low-grade glioma had been controversial in the past, it is now widely accepted that maximal EOR is a crucial factor in determining OS. [2] [3] [4] 6, 10, 13, 29, [32] [33] [34] [35] [36] [37] [38] In this study, we provide evidence that EOR is associated with improved OS and improved PFS2. Furthermore, the removal of all FLAIRdemarcated disease with subpial dissection at initial operation or subsequent operation of low-grade tumors was associated with improvement in long-term survival compared with simply removing .90% of observable tumor (Table 2) . Moreover, our data demonstrate that although radiation was associated with an improved PFS1, it did not affect PFS2 and was not associated with improved OS, as previously reported with Radiation A, the presence of any residual after the initial operation suggested a significant detrimental impact on overall survival (OS; 16.7 6 1.8 vs 10.5 6 1.0 years; P= .004). B, the presence of any residual after recurrence and reresection suggested a significant detrimental impact on OS (17.2 6 1.7 vs 9.8 6 0.9 years; P , .001).
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Therapy Oncology Group 22845 (In fact, upfront radiotherapy was associated with decreased OS on univariate analysis and a higher rate of malignant degeneration). 8, 39 Similarly, chemotherapy did not seem to affect OS or PFS but was associated with decreased PFS2. Interestingly, a low KPS score (,80) was not associated with poorer outcome until the second surgical recurrence. It should be noted, however, that the influence of more malignant phenotypes at second surgical recurrence clouds the interpretation of associated risk factors and treatments.
Finally, the use of functional mapping to improve EOR helped achieve safe outcomes with an average KPS score of 88.7 6 1.7 after the second operation; however, its use was not associated with an OS benefit, likely because of limited EOR secondary to invaded functional cortex. In a focused multivariate analysis, EOR at the first and second operations remained positively prognostic, regardless of patient age, pathology, chemotherapy, and radiation. FIGURE 4. A, upfront radiation was associated with significantly worsened overall survival (16.6 61.6 vs 11.4 6 1.0 years; P = .03). B, upfront radiation was associated with significant effects on progression-free survival to the first recurrence (4.64 6 0.5 vs 7.2 6 0.7; P = .007).
FIGURE 5.
The presence of any residual on repeat surgery was associated with significantly less time to second progression (7.3 6 2.3 vs 2.3 6 0.343; P , .001).
FIGURE 6.
In patients who recur and maintain low-grade status, administration of chemotherapy was associated with decreased time to second progression (7.5 6 1.2 vs 3.6 6 0.5; P = .03).
Subgroup analyses corroborated several underreported phenomena. First, in 10 patients, there was subtle, demonstrable change in the tumor seen on surveillance imaging, which heralded areas of subsequent malignant degeneration ( Figure 7) . Moreover, these patients suffered worse OS compared with patients who retained low-grade status at time of repeat resection. Despite the inherent advantages of reanalyzing images retrospectively, these data suggest that these subtle changes in tumor appearance on MRI need to be carefully evaluated and considered for surgery because they appear to herald ensuing malignant degeneration. Certainly, FLAIR-related changes may be treatment related, but these changes may also signal a window of opportunity when aggressive repeat resection can limit progression and enhance OS. Anxiety about repeated operations should be tempered by our data showing similar OS for patients undergoing 3 or 4 resections and for patients who had undergone 2 resections. Thus, these data suggest the need for better surveillance imaging modalities to assist in the determination of disease progression or impending disease progression. Recent reports suggest that magnetic resonance spectroscopy or magnetic resonance imaging combined with positron emission tomography may have a role in identifying tumor change before anaplastic transformation and could easily be incorporated into routine surveillance imaging. [40] [41] [42] [43] [44] [45] Interestingly, pathology at diagnosis did not seem to influence OS. Of course, no patients in this series were followed up without treatment, perhaps suggesting that aggressive resection influences the clinical behavior of gliomas regardless of histology, although such an assertion is speculative, given the data showing disparate outcomes by pathology 3, 4 and by treatment response in codeleted oligodendrogliomas. [46] [47] [48] [49] [50] An unexpected finding was that upfront radiation was associated with significantly decreased OS, by approximately 5 years, which, to the best of our knowledge, has been reported only once before in the literature. 4 Even in subgroup analysis of patients with partially resected tumors, upfront radiation was associated with a significant survival disadvantage (11.7 6 0.7 vs 9.5 6 1.1 years; P = .05). Previous studies have noted an improvement in progression-free survival when surgery is followed by radiation for low-grade gliomas but no effect on OS. 51 As a result, some have argued for the use of postoperative radiation in subtotally resected low-grade lesions. 30 Although our data noted an association with improvement in PFS, the association with a decrease in OS was not expected, nor was the increased rate of malignant degeneration, particularly in light of the recent findings in Radiation Therapy Oncology Group 9802. 52 These effects with regard to radiation may reflect changes in tumor biology affected by ionizing therapy, perhaps leading to more malignant phenotypes at recurrence. Moreover, the effect of molecular status on radiation response may also play a role, although this analysis was not possible in our series. Alternatively, it may have been that certain patients had a more worrisome clinical picture postoperatively, which may have pushed their clinicians into recommending adjuvant radiotherapy; therefore, this more worrisome clinical picture may have reflected more malignant biology and thus may explain the worse OS. Finally, the effects of sample size may have played a role in the finding of worse OS after upfront radiation therapy.
Furthermore, the use of chemotherapy at recurrence on those patients who maintained low-grade pathology was associated with a significantly decreased PFS2, although no difference in OS was observed. This again may reflect changes to tumor biology affected by genotoxic treatment, as has been reported elsewhere with lowgrade gliomas. 53 It may also reflect the combined effects of chemoradiotherapy because many patients received both therapies at recurrence. Additionally, there was a trend of improved OS in those patients treated with PCV as opposed to temozolomide. Although there has been no conclusive evidence that PCV is superior to temozolomide in the treatment of primary or recurrent low-grade glioma, a recent trial showed significant benefit with adjuvant PCV in codeleted anaplastic 
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oligodendrogliomas. 52 These differences and others may be a result of the relatively long follow-up of our study (15.9 years) compared with others such as the European Organisation for Research and Treatment of Cancer 22845 (median follow-up, 7.7 years). 8 However, these results should be received with caution, given the low sample size of patients with recurrent lowgrade tumors who received adjuvant PCV (n = 4).
Additionally, this study group differs from other study populations in the available literature in that the patients at diagnosis were ,40 years of age, had focal tumors that did not cross the midline (94%) with an average tumor diameter of 4.75 6 0.25, had good performance status, and were minimally symptomatic. Moreover, age ,40 years at recurrence, the presence of seizures, tumor enhancement, and pathology at diagnosis did not seem to be associated with OS. 2, 3, 21, 31 Therefore, the prognostic variables identified in the Bauman et al 3 and Pignatti et al 2 studies do not apply in this patient population or may be a reflection of sample size. Therefore, this study represents patients with resectable lowgrade gliomas that remained resectable at recurrence, which is a relatively common occurrence in a modern glioma practice. This may partly explain the discrepancy of the predicted vs actual survival results in a comparison of the Bauman et al 3 RPA with our data (Table 3) . This feature of resectablitity may also explain why OS for patients who maintained low-grade status averaged nearly 15 years despite having surgical recurrences (average for entire cohort, 13 years). This is in contradistinction to a recent large study of patients with low-grade gliomas whose average survival was 6.5 years 54 and the Bauman et al 3 study with an average OS of 10.6 years in group IV patients. Even in studies that have selected for good prognostic factors such as age ,40 years, tumor size ,6 cm, and tumors that do not cross the midline, the average OS was 7.7 years. 21, 55 In addition, average progression-free survival was nearly 6.5 years for the entire cohort, 7.1 years in those who received adjuvant radiotherapy, and 4.6 years in those who did not receive radiotherapy. This progression-free survival data is improved compared with recent studies showing progression-free survival ranging from 4.5 to 5.3 years, even with adjuvant radiotherapy 8, 56 ; therefore, the overarching difference may have been the guiding principle of maximal, safe resection, perhaps leading to improved outcome. Moreover, performance status dropped below 80 in only 7 patients after their second surgery; despite this, there was no change in OS as a result, suggesting that repeat resections do not portend worsening neurological outcomes and quality of life, provided that measures ensuring surgical safety such as functional mapping are used. Thus, we believe that our results suggest that maximal, safe resective surgery at diagnosis and at recurrence is essential for optimizing survival. Surgical adjuncts that enhance EOR such as intraoperative MRI or intraoperative molecular imaging may prove to be crucial in further enhancing EOR while maintaining safety. 57, 58 In the only other study that evaluated surgery at relapse, Ahmadi et al 26 found that patients with complete resections initially and at relapse had significantly better survival than those with subtotal resections or those limited to only 1 initial operation. However, they did not find an impact on progression-free survival at either the first or second relapse, in contrast to the results of our study. Interestingly, the average OS for those patients was 16.1 years (74% underwent reoperation), which is very similar to our results with only reoperated patients.
Limitations
This study has significant limitations. First, because the vast majority of the patients in this study presented before the modern era of routine molecular subclassification, it is unclear whether 1p/ 19q deletion status, IDH-1 mutation status, MGMT methylation status, or other heretofore unidentified molecular or metabolic phenotypes were more important in determining outcome than the role of repeat surgery and EOR. [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] The lack of such data represents an inherent weakness in the study, which needs to be addressed in the future. Second, as a retrospective study, patient follow-up was not standardized, and the study itself is subject to the usual biases that controlled studies can avoid. Third, our study failed to note a benefit of aggressive resection in improving PFS1, although it showed an effect on OS and PFS2. This probably reflects our sample size rather than any attribute related to the pathobiology of the disease or its treatment. In addition, a substantial majority (71%) of patients had an aggressive resection of .90% of FLAIR disease and 96% had a resection of .80% of FLAIR disease at their initial operation. Both of these thresholds have been shown to positively affect outcome and perhaps to play a role in the lack of observable difference in PFS1. 38, 69 Because our criteria for indicating the presence of residual FLAIR disease postoperatively were strict, it may be that in some instances there was an underreporting of FLAIR-negative disease owing to postsurgical change. Additionally, neurocognitive outcomes after repeat neurosurgical operations were not routinely studied in these patients; such data would undoubtedly inform on the quality of life that these patients with repeated operations experience. In addition, the clinical databases were robust enough to capture surgical patients as studied here but not large enough to know how many low-grade gliomas were seen at our institution in total during the study period. Therefore, it cannot be assumed that our results apply to the entire population of patients who present with a low-grade glioma for the first time. Finally, because this is not a randomized study, selection bias regarding which patient received which treatments could not be controlled for and may represent a significant influence on our results. That said, this is the largest study to date focused on reoperated low-grade gliomas with long-term follow-up (mean, 15.9 years).
CONCLUSION
Patients with low-grade gliomas treated with aggressive resections and reresections can experience long-term survival. These resections seem to affect OS much more significantly than adjuvant radiotherapy and chemotherapy. These results favor reoperation for recurrent low-grade gliomas. In addition, new imaging modalities to follow up tumors and to detect impending progression are needed because oftentimes these areas of progression are resectable.
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